AVEO Pharmaceuticals (AVEO) Tops Q3 EPS by 23c, Offers Gudiance

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/26/2026

1. ORCL
2. SPY
3. FLG
4. META
5. FICO
6. GMAB
7. ACCV
8. LLY
9. TSLA
10. SPCX

Go back to AVEO Pharmaceuticals (AVEO) Tops Q3 EPS by 23c, Offers Gudiance

AVEO Oncology Reports Third Quarter 2015 Financial Results and Provides Business Update

November 9, 2015 6:30 AM EST

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- AVEO Oncology (NASDAQ: AVEO) today reported financial results for the third quarter ended September 30, 2015 and provided a business update.

We completed partnerships for two of AVEOs lead programs in the third quarter in addition to making progress toward our proposed plans to submit a European Marketing Authorization Application (MAA) for tivozanib in renal cancer and initiate a pivotal study in this indication in the U.S., said Michael Bailey, president and chief executive officer. As we work through recently initiated discussions with the SEC, we remain focused on... More